**Core Concept**
Actinomycin D is a chemotherapeutic agent used to treat various types of cancer. Its mechanism of action involves the inhibition of RNA synthesis, specifically by binding to DNA and preventing the initiation of transcription.

**Why the Correct Answer is Right**
Actinomycin D binds to the minor groove of DNA, specifically to the GC-rich regions, and prevents the binding of RNA polymerase to the DNA template. This results in the inhibition of transcription of mRNA, which in turn prevents the synthesis of proteins necessary for cell growth and division. Actinomycin D also has a high affinity for double-stranded DNA, which allows it to bind to specific DNA sequences and inhibit the transcription of genes involved in cell proliferation.

**Why Each Wrong Option is Incorrect**
**Option A:** Actinomycin D does not work by inhibiting the cell cycle at the G2/M phase, as this is the mechanism of action of other chemotherapeutic agents such as vinca alkaloids and taxanes.
**Option B:** Actinomycin D does not work by inducing DNA damage, as this is the mechanism of action of other chemotherapeutic agents such as alkylating agents and platinum-based drugs.
**Option C:** Actinomycin D does not work by inhibiting the enzyme topoisomerase, as this is the mechanism of action of other chemotherapeutic agents such as etoposide and teniposide.

**Clinical Pearl / High-Yield Fact**
Actinomycin D is a potent inhibitor of RNA synthesis, and its mechanism of action is distinct from other chemotherapeutic agents that target DNA or protein synthesis. As a result, it is often used in combination with other agents to treat various types of cancer.

**Correct Answer:** D. Inhibiting RNA synthesis by binding to DNA and preventing the initiation of transcription.